首页> 外文期刊>BMC Cancer >Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer
【24h】

Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer

机译:谵妄观测筛查量表(DOS)作为晚期癌症患者的谵妄筛查工具

获取原文
           

摘要

The Delirium Observation Screening Scale (DOS) was developed to facilitate early recognition of delirium by nurses during routine clinical care. It has shown good validity in a variety of patient populations, but has not yet been validated in hospitalized patients with advanced cancer, although the DOS is commonly used in this setting in daily practice. The aim of this study was to evaluate the accuracy of the DOS in hospitalized patients with advanced cancer using the revised version of the Delirium Rating Scale (DRS-R-?98?99.9% (95% CI 96.1-100.0). The DOS is an accurate screening tool for delirium in patients with advanced cancer. Since it has the benefit of being easily implicated in daily practice, we recommend to educate caregivers to screen patients with advanced cancer by DOS analysis. By early recognition and adequate treatment of this distressing delirium syndrome the quality of life of patients with advanced cancer can be improved. ClinicalTrials.gov Identifier NCT01539733 (Feb 27, 2012 - retrospectively registered), Netherlands Trial Register NTR2559 (Oct 7, 2010).
机译:发展谵妄观察筛查规模(DOS)是为了促进常规临床护理期间护士早日识别谵妄。它在各种患者群体中表现出良好的有效性,但尚未在住院患者患有晚期癌症的患者中验证,尽管DOS通常用于日常实践中的这种环境。本研究的目的是利用谵妄评级规模的修订版(DRS-R-?98?99.9%(95%CI 96.1-100.0),评估住院治疗晚期癌症患者的DOS的准确性。该DOS是晚期癌症患者的谵妄精确筛选工具。由于具有在日常生实践中轻易涉及的益处,我们建议通过DOS分析向护理人员筛查患有先进癌症的患者。通过早期识别和对这种令人痛苦的谵妄的充分治疗综合征可以提高晚期癌症患者的生活质量。Clincachtrials.gov标识符NCT01539733(2012年2月27日 - 回顾性注册),荷兰试验登记NTR2559(2010年10月7日)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号